HIK Hikma Pharmaceuticals Plc

TIDMHIK

RNS Number : 2906E

Hikma Pharmaceuticals Plc

05 November 2020

Hikma Pharmaceuticals PLC - Board and Committee Changes

London, 5 November 2020 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) ( Hikma ) Further to our announcement on 27 February 2020, the Board has determined the point at which it will implement the previously announced succession arrangements.

On 1 December 2020, Pat Butler will become the chair of the Nomination and Governance Committee and Senior Independent Director. On the same day, Pat's responsibilities for chairing the Audit Committee will be handed over to Douglas Hurt.

On 18 December 2020, Robert Pickering, who has served for nine years, will retire from the Board.

Said Darwazah, Executive Chairman, said: 'Robert has been an excellent Senior Independent Director and Chair of the Nomination and Governance Committee. Robert and I have worked very closely on developing the Board which has ensured that we are very well positioned for the future. His broad business perspective, focused and efficient approach and consensual style will be missed. Robert has been a great friend to Hikma and me, I wish him well for the future.

I am looking forward to working more closely with Pat and Douglas as we move forward.'

-- ENDS --

Enquiries:

Hikma Pharmaceuticals PLC

Peter Speirs, Company Secretary +44 (0)20 7399 2772

Susan Ringdal, EVP Strategy and Global Affairs +44 (0)20 7399 2760

About Hikma

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

(LEI:549300BNS685UXH4JI75)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAUPGPWGUPUGQC

(END) Dow Jones Newswires

November 05, 2020 06:30 ET (11:30 GMT)

Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Mar 2024 a Apr 2024

Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Apr 2023 a Apr 2024